Updated Jul 16, 2026
Yea Christopher has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.79M.
Christopher Yea is the Chief Development Officer at KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-11 | KALV | KalVista Pharmaceuticals, Inc. | D — Derivative transaction | 229.9K | $0.00 | |
| 2026-05-29 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 33.8K | $26.78 | $905K |
| 2026-05-29 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 33.8K | $7.07 | $239K |
| 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.0K | $26.78 | $53K |
| 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 3.1K | — | |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.4K | $26.78 | $63K |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 3.8K | — | |
| 2026-05-19 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.1K | $26.76 | $30K |
| 2026-05-19 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 1.8K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 4.3K | $15.57 | $68K |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 3.1K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 3.8K | — | |
| 2026-02-20 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.1K | $15.00 | $17K |
| 2026-02-20 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 1.8K | — | |
| 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.0K | $13.42 | $26K |
| 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 3.1K | — | |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.4K | $13.22 | $31K |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 3.8K | — | |
| 2025-08-17 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.6K | $13.19 | $35K |
| 2025-08-17 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 4.2K | — |
Christopher Yea is the Chief Development Officer at KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. He has been involved in multiple SEC filings related to his role at the company.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 12 open-market sales ($1.79M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Yea Christopher profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.